Sun Pharmaceuticals settles drug patent litigation with pharma giants

Date: 2018-01-17   Author: Saipriya Iyer  Category: #industry

Sun Pharmaceuticals settles drug patent litigation with pharma giants

Sun Pharmaceuticals Industries Limited, a key player across the pharmaceuticals industry, has reportedly entered into a pact with Pharma giants Allergan Plc & Ironwood Pharmaceuticals Inc. for resolving the patent dispute over the Linzess drug in the United States.

According to some of the key officials of Sun Pharma, the case related to the drug patent was filed against the firm in response to its abbreviated new drug application under which Sun Pharma is seeking USFDA approval for promoting the generic form of Linzess drug. Medical practitioners have stated that the prescribed medicine is used in treating chronic idiopathic constipation and irritable bowel syndrome in the elderly. As per statistics, the revenue from the sale of the drug had hit USD 506 million in the third quarter of last year, demonstrating a 12% y-o-y growth. It has been reported that in the last quarter of 2017 however, Linzess recorded sales worth USD 191 million, a growth of nearly 16% y-o-y.  As per the market projections, the drug is likely to accrue a revenue of over USD 1 billion as a result of its high demand and favorable purchasing patterns.

As a part of the deal, Ironwood Pharmaceuticals and Allergan Plc will provide a license to Sun Pharmaceuticals to promote Linzess generic across the U.S., effective from 1st February 2031, or even prior to this date, subject to specific conditions. It has been learnt that after the settlement, the patent lawsuit against Sun Pharmaceuticals filed by the two pharma giants will be dismissed. However, as per the key officials of Sun Pharma, the pact is still subject to normal regulatory approvals.

Industry analysts have anticipated that the settlement will have a positive impact on the business growth of Sun Pharma. After the firm’s strategic decision to settle the patent dispute, the firm’s stocks had jumped up from INR 576.40 to INR 578.10 yesterday.



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Innovations in surveillance system—a growth enabler in air traffic management

Author: Saipriya Iyer

Transforming air traffic management into a more interoperable, automated, modular and scalable system will potentially reap rewards from developments in virtualization and digital technologies. Seamless high-performing...


Stents industry to witness robust technological innovations with ongoing R&D activities

Author: Pankaj Singh

One of the fastest emerging verticals within the healthcare and medical devices space, the global stents market is set to witness numerous interesting trends in the coming years. Ongoing research and development in the...


Amazon India launches ‘Select’ program to assist emerging brands

Author: Shikha Sinha

E-commerce giant Amazon has reportedly started a new program called ‘Select’ in India. As per trusted sources, the program will enable emerging brands in the country to get access to a suite of brand buildi...